AIDS Therapies (ALX40-4C)

New Treatment Strategy To Block HIV Holds Promise

Published in AIDS Weekly, May 13th, 1996

A laboratory study by researchers at the University of California, Los Angeles (UCLA) AIDS Institute and West Los Angeles Veterans Administration Medical Center (VAMC) has found that a drug can block infection by HIV strains associated with the killing of CD4 cells.

Current therapies for HIV infection, such as zidovudine (AZT), attack the virus after it already has invaded a cell, said study leader William O'Brien, M.D., West Los Angeles VAMC and UCLA associate professor of medicine.

In contrast, O'Brien and his colleagues found that a drug called ALX40-4C appeared to block certain strains of HIV by preventing the virus from entering the cell. "This...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-05-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry